In this weeks news:
- Low oxygen levels could drive cancer growth, research suggests
- Mutant Kras drives pancreatic cancer maintenance via metabolic pathways
- Genomics In The Journals | GenomeWeb Daily News | GenomeWeb
- CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer – MarketWatch
- European-Hospital: Oral vaccination against pancreatic tumours
- Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic Cancer – MarketWatch
- BBC News – ‘Brake gene’ turned off in pancreatic cancer
- Whole genome sequencing not informative for all, Johns Hopkins study shows | e! Science News
With sharp declines in the cost of whole genome sequencing, the day of accurately deciphering disease risk based on an individual’s genome may seem at hand. But a study involving data of thousands of identical twins by Johns Hopkins investigators finds that genomic fortune-telling fails to provide informative guidance to most people about their risk for most common diseases, and warns against complacency born of negative genome test results. Findings from the Johns Hopkins researchers’ evaluation of the predictive value of whole genome sequencing are published online April 2 in Science Translational Medicine.
- ApoCell’s Circulating Tumor Cell (CTC) Capture Technology First to Reliably Detect and Recover Deadly Liver Cancer Cells – MarketWatch
Scientists at ApoCell, Inc., in partnership with researchers at Virginia Commonwealth University (VCU) Massey Cancer Center, have used the company’s revolutionary ApoStream(TM) technology for a new first —the reliable isolation and recovery of circulating tumor cells (CTCs) from patients with hepatocellular carcinoma (HCC), one of the most common forms of liver cancer. Globally, liver cancer is the third most common cause of cancer-related deaths.
Here are the latest additions to the Mendeley Pancreatic Cancer Genomics collection.
- Bioinformatic identification of proteins with tissue… [BMC Med. 2012] – PubMed – NCBI
- The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.
- Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene.
- Circulating MicroRNAs in Serum of Human K-ras Oncogene Transgenic Rats With Pancreatic Ductal Adenocarcinomas.
- Plasma Shh Levels Reduced in Pancreatic Cancer Patients.
- RLIP76 Regulates PI3K/Akt Signaling and Chemo-Radiotherapy Resistance in Pancreatic Cancer.
- Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1.
- P38? MAP Kinase as a therapeutic target for pancreatic cancer.
- Invasive markers identified by gene expression profiling in pancreatic cancer.
- HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
- Hypoxia-inducible factor-1 up-regulates the expression of Toll-like receptor 4 in pancreatic cancer cells under hypoxic conditions.
- Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp–/rag2– mice
- The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis.
- Mouse models of pancreatic cancer.
- MicroRNAs in pancreatic cancer metabolism.
- Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.
- Tif? Suppresses Murine Pancreatic Tumoral Transformation by an Smad4-Independent Pathway.
- The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1? targeted gene expression.
- Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype.
- Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.